The Spore Report
Dispatches from The Spore Report — curated from medical journals, research papers, podcasts, and news outlets around the world.
Never Miss What Matters
One weekly email. The best psilocybin research, podcasts, and news from trusted sources around the world — no searching required.
Psilocybin for Opioid Alternatives: What We Know So Far
A news segment from New York explored the possibility that psilocybin, the compound found in certain mushrooms, could serve as an alternative or complement to opioid prescriptions. The…
Psilocybin for Mental Health: Pa. Legislature Weighs Access
In September 2025, Pennsylvania House Democrats convened a policy committee hearing on a bipartisan bill that would legalize psilocybin therapy in the state, but only after federal FDA…
Minnesota Psilocybin Research Bill: What Lawmakers Approved
Minnesota state lawmakers are on the verge of approving legislation that would authorize federally funded psilocybin research. The bill does not legalize psilocybin for general use. It is…
Psilocybin for PTSD: Trials, Laws, and Early Evidence
In January 2026, the FDA accepted Compass Pathways’ Investigational New Drug Application to study its synthetic psilocybin compound, COMP360, as a possible therapy for PTSD. A separate randomized…
Psilocybin and Inflammation: What the Research Shows
In a study of 60 healthy adults, a single dose of psilocybin was associated with significantly reduced levels of the inflammatory markers TNF-alpha and IL-6 over the following…
Psilocybin for Anxiety: Ontario Clinical Trial Launches
Kingston Health Sciences Centre in Ontario has launched a regulated clinical trial examining whether psilocybin-assisted therapy can reduce anxiety. The trial is in an early enrollment phase, and…
Psilocybin and Cognition: What 20 Studies Found
A 2024 systematic review pooled 20 studies and 2,959 participants to assess how psilocybin affects thinking. Results were mixed: global cognition and processing speed were largely unchanged in…
Senate Bill S.4031: Federal Psychedelic Research at the VA
Senate Bill S.4031, the Innovative Therapies Centers of Excellence Act, would authorize the Department of Veterans Affairs to establish specialized centers studying psilocybin, MDMA, ibogaine, ketamine, and 5-MeO-DMT…
Microdosing Days vs. Rest Days: Six Domains Compared
In a prospective, naturalistic survey of 1,435 adults who microdose psychedelics, researchers found that self-reported scores for wellbeing, productivity, creativity, connectedness, contemplation, and focus were each significantly higher…
Psilocybin for Veteran PTSD: Early Trial Remission Rates
A clinical trial examined psilocybin-assisted therapy in veterans diagnosed with PTSD and reported striking remission rates among participants. This is early-phase human research, and the full details of…
You've Come This Far. Stay Informed.
Join our free weekly newsletter and get the best psilocybin research, medical journals, podcasts, and news — hand-curated from trusted sources around the world and delivered straight to your inbox.